Evidence map›Paper›PMID 35504177›Full record

ArticleTranslational oncology2022

Preliminary study on the role of the C5orf46 gene in renal cancer.

Ming Ma, Zhicheng Zhang, Yifu Liu, Zhilong Li, Shengqiang Fu, Qiang Chen, Siyuan Wang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Ming MaDepartment of Urology, The First Affiliated Hospital of Nanchang University, No. 17, Yongwai Center Street, Donghu District, Nanchang, Jiangxi 330006, China.
Zhicheng ZhangDepartment of Urology, The First Affiliated Hospital of Nanchang University, No. 17, Yongwai Center Street, Donghu District, Nanchang, Jiangxi 330006, China.
Yifu LiuDepartment of Urology, The First Affiliated Hospital of Nanchang University, No. 17, Yongwai Center Street, Donghu District, Nanchang, Jiangxi 330006, China.
Zhilong LiDepartment of Urology, The First Affiliated Hospital of Nanchang University, No. 17, Yongwai Center Street, Donghu District, Nanchang, Jiangxi 330006, China.
Shengqiang FuDepartment of Urology, The First Affiliated Hospital of Nanchang University, No. 17, Yongwai Center Street, Donghu District, Nanchang, Jiangxi 330006, China.
Qiang ChenDepartment of Urology, The First Affiliated Hospital of Nanchang University, No. 17, Yongwai Center Street, Donghu District, Nanchang, Jiangxi 330006, China.
Siyuan WangDepartment of Urology, The First Affiliated Hospital of Nanchang University, No. 17, Yongwai Center Street, Donghu District, Nanchang, Jiangxi 330006, China. Electronic address: 876844845@qq.com.
Nanchang University · CNFirst Affiliated Hospital of Nanchang University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundC5orf46 has been found to have antibacterial and anti-inflammatory effects via sequencing and microarray technologies, but its effects on cancer are unclear.

methodsC5orf46 expression in renal cancer patients and cell lines was measured by quantitative polymerase chain reaction (qPCR). RNA sequencing data and clinicopathological information from renal cancer patients extracted from The Tumor Genome Atlas (TCGA) were analyzed to evaluate the prognostic value of C5orf46. The role of C5orf46 in vitro was verified by migration, proliferation and apoptosis experiments in renal cancer cell lines. Furthermore, the transcriptome of renal cancer cell lines with C5orf46 knocked down was sequenced to analyze potential signaling network pathways. Finally, the possible mechanisms of C5orf46 involvement in renal cancer development were analyzed by evaluating the immune microenvironment, mutation status and methylation levels.

resultsC5orf46 was highly expressed in renal cancer and was an independent prognostic factor. In vitro cell experiments showed that inhibition of C5orf46 expression could reduce renal cancer cell proliferation and migration and increase apoptosis. Transcriptomic sequencing after knockdown of C5orf46 in renal cancer cells revealed that it is involved in the malignant phenotype and immune microenvironment regulation of renal cancer. Finally, public databases suggest that C5orf46-related immune cell infiltration, mutational potential, and low methylation levels may contribute to poor prognosis in renal cancer.

conclusionThese findings suggest that C5orf46 is associated with renal cancer progression and could be a potential target for improving renal cancer prognosis.

Indexed as

BiomarkerC5orf46Immune cellsPrognosticRenal cancer

Identifiers

PMID35504177
PMCPMC9079122
OpenAlexW4225163419

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.